Glaxo Group Limited

Glaxosmithkline Intellectual Property Development Limited

Agenus Inc.

Domantis Limited

Glaxon Group Limited

Oliver Schon

Haiqun Liu

Elena De Angelis

Carolyn Enever

David I Israel

Ghotas Evindar

Ninad V Prabhu

Peter Kumpalume

Christine Patricia Donahue

David Paolella

Letian Kuai

Gregory Paul Winter

Jasper Clube

Nicholas Stuart Wilson

Ian M Tomlinson

Olga Ignatovich

Philip Jones

Jeremy Dale Waight

Laurent S Jespers

Christopher Plummer

Benjamin Maxime Morin

Rudolf M T De Wildt

Malgorzata Pupecka-Swider

Shawn Michael Jennings

Emmanuel Cyrille Pascal Briend

Lucy J Holt

Thil Dinuk Batuwangala

Spencer Campbell

Haren Arulanantham

Edward Coulstock

Leo C James

Lucy Holt

The instant disclosure provides antibodies that specifically bind to CD73 (e.g., human CD73) and antagonize CD73 function. Also provided are anti-CD73 antibodies that further comprise a TGF&#x3b2;-binding moiety or a VEGF-binding moiety. The instant disclosure additionally provides pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Anti-CD73 antibodies and methods of use thereof

The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-11, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.

Anti-serum albumin binding variants

Compounds useful for affinity chromatography as presented, more particularly for use in affinity chromatography to purify serum albumin, especially human serum albumin (HSA) and fusion proteins thereof. Methods for extending the half-life of therapeutic agents are also presented, particularly therapeutic peptide agents and small molecules, such as by conjugation of compounds described herein to the therapeutic peptide or small molecule, which, upon administration, binds to HSA, thereby providing a prolonged release of the therapeutic agent.

Compounds for affinity chromatography and for extending the half-life of a therapeutic agent

Compounds useful for affinity chromatography as presented, more particularly for use in affinity chromatography to purify serum albumin, especially human serum albumin (HSA) and fusion proteins thereof. Methods for extending the half-life of therapeutic agents are also presented, particularly therapeutic peptide agents and small molecules, such as by conjugation of compounds described herein to the therapeutic peptide or small molecule, which upon administration, binds to HSA, thereby providing a prolonged release of the therapeutic agent.

The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-14, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.

The invention provides a dual-specific ligand comprising a first immunoglobulin variable domain having a first binding specificity and a complementary or non-complementary immunoglobulin variable domain having a second binding specificity.

Ligand

The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domains, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.

The invention relates to improved anti-serum albumin immunoglobulin single variable domains, as well as ligands and drug conjugates comprising such variable domains, compositions, nucleic acids, vectors and hosts.

Anti-serum albumin single variable domains

An inhibitor of the aggregation of immunoglobulin chains is provided. The inhibitor may comprise or consist of a polypeptide which comprises or consists of (a) an amino acid sequence corresponding to the amino acid sequence of the FR1 region of an immunoglobulin light chain variable domain, or part thereof which includes amino acid residue 12, (b) an amino acid sequence corresponding to the amino acid sequence of the immunoglobulin-binding domain of bacterial superantigen Protein L, or part thereof, and/or (c) an amino acid sequence corresponding to the amino acid sequence of the immunoglobulin-binding domain of streptococcal protein G, or part thereof, or a variant, fusion or derivative thereof, or a fusion of a variant or derivative thereof which retains the ability of the parent polypeptide to inhibit aggregation of immunoglobulin chains, or domains thereof. Other versions of the inhibitor are also provided.

Prevention of aggregation of immunoglobulin light or heavy chains

Growing community of inventors

Cambridge, United Kingdom

Oliver Schon